Compare TIRX & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIRX | XAIR |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 10.5M |
| IPO Year | 2021 | N/A |
| Metric | TIRX | XAIR |
|---|---|---|
| Price | $0.12 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 93.9M | 22.5M |
| Earning Date | 08-22-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,802,000.00 |
| Revenue This Year | N/A | $127.85 |
| Revenue Next Year | N/A | $179.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 158.74 | 147.74 |
| 52 Week Low | $0.07 | $0.67 |
| 52 Week High | $6.45 | $10.40 |
| Indicator | TIRX | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 41.96 |
| Support Level | $0.07 | $1.43 |
| Resistance Level | $0.30 | $2.26 |
| Average True Range (ATR) | 0.19 | 0.22 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 2.08 | 1.55 |
Tian Ruixiang Holdings Ltd is an Insurance Brokerage firm. It distributes a wide range of insurance products, which are categorized into two groups; property and casualty insurance, such as commercial property insurance, liability insurance, accidental insurance, and automobile insurance; and other insurances, such as health insurance, life insurance, and miscellaneous insurances. It also generates a small amount of revenue from risk management services. The firm act on behalf of its customers seeking insurance coverage from insurance companies. It generates revenue from the provision of insurance brokerage services.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.